Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, John F. Heitner et al.|Circulation|2014Cited by 1k
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D. Solomon, Marc A. Pfeffer, Brian Claggett et al.|European Heart Journal|2015Cited by 524
Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic CardiomyopathyCarolyn Y. Ho, Scott D. Solomon, Nancy K. Sweitzer et al.|Circulation|2002Cited by 424
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trialJordana B. Cohen, Julio A. Chirinos, Thomas C. Hanff et al.|The Lancet Respiratory Medicine|2021Cited by 224
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial ProtocolJordana B. Cohen, Julio A. Chirinos, Thomas C. Hanff et al.|Journal of Clinical Hypertension|2020Cited by 19